208 related articles for article (PubMed ID: 30195779)
1. Morpholino Antisense Oligomers as a Potential Therapeutic Option for the Correction of Alternative Splicing in PMD, SPG2, and HEMS.
Tantzer S; Sperle K; Kenaley K; Taube J; Hobson GM
Mol Ther Nucleic Acids; 2018 Sep; 12():420-432. PubMed ID: 30195779
[TBL] [Abstract][Full Text] [Related]
2. PLP1 splicing abnormalities identified in Pelizaeus-Merzbacher disease and SPG2 fibroblasts are associated with different types of mutations.
Bonnet-Dupeyron MN; Combes P; Santander P; Cailloux F; Boespflug-Tanguy O; Vaurs-Barrière C
Hum Mutat; 2008 Aug; 29(8):1028-36. PubMed ID: 18470932
[TBL] [Abstract][Full Text] [Related]
3. PLP1 gene duplication causes overexpression and alteration of the PLP/DM20 splicing balance in fibroblasts from Pelizaeus-Merzbacher disease patients.
Regis S; Grossi S; Corsolini F; Biancheri R; Filocamo M
Biochim Biophys Acta; 2009 Jun; 1792(6):548-54. PubMed ID: 19376225
[TBL] [Abstract][Full Text] [Related]
4. Altered PLP1 splicing causes hypomyelination of early myelinating structures.
Kevelam SH; Taube JR; van Spaendonk RM; Bertini E; Sperle K; Tarnopolsky M; Tonduti D; Valente EM; Travaglini L; Sistermans EA; Bernard G; Catsman-Berrevoets CE; van Karnebeek CD; Østergaard JR; Friederich RL; Fawzi Elsaid M; Schieving JH; Tarailo-Graovac M; Orcesi S; Steenweg ME; van Berkel CG; Waisfisz Q; Abbink TE; van der Knaap MS; Hobson GM; Wolf NI
Ann Clin Transl Neurol; 2015 Jun; 2(6):648-61. PubMed ID: 26125040
[TBL] [Abstract][Full Text] [Related]
5. PMD patient mutations reveal a long-distance intronic interaction that regulates PLP1/DM20 alternative splicing.
Taube JR; Sperle K; Banser L; Seeman P; Cavan BC; Garbern JY; Hobson GM
Hum Mol Genet; 2014 Oct; 23(20):5464-78. PubMed ID: 24890387
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of PLP1 gene mutations in patients with the classical form of the Pelizaeus-Merzbacher disease.
Hoffman-Zacharska D; Mierzewska H; Szczepanik E; Poznański J; Mazurczak T; Jakubiuk-Tomaszuk A; Mądry J; Kierdaszuk A; Bal J
Med Wieku Rozwoj; 2013; 17(4):293-300. PubMed ID: 24519770
[TBL] [Abstract][Full Text] [Related]
7. Deletion of a splicing enhancer disrupts PLP1/DM20 ratio and myelin stability.
Wang E; Dimova N; Sperle K; Huang Z; Lock L; McCulloch MC; Edgar JM; Hobson GM; Cambi F
Exp Neurol; 2008 Dec; 214(2):322-30. PubMed ID: 18835559
[TBL] [Abstract][Full Text] [Related]
8. Clinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brain.
Bachstetter AD; Webster SJ; Van Eldik LJ; Cambi F
J Neuroinflammation; 2013 Dec; 10():146. PubMed ID: 24314267
[TBL] [Abstract][Full Text] [Related]
9. Splice-site contribution in alternative splicing of PLP1 and DM20: molecular studies in oligodendrocytes.
Hobson GM; Huang Z; Sperle K; Sistermans E; Rogan PK; Garbern JY; Kolodny E; Naidu S; Cambi F
Hum Mutat; 2006 Jan; 27(1):69-77. PubMed ID: 16287154
[TBL] [Abstract][Full Text] [Related]
10. A case of complicated spastic paraplegia 2 due to a point mutation in the proteolipid protein 1 gene.
Lee ES; Moon HK; Park YH; Garbern J; Hobson GM
J Neurol Sci; 2004 Sep; 224(1-2):83-7. PubMed ID: 15450775
[TBL] [Abstract][Full Text] [Related]
11. PLP overexpression perturbs myelin protein composition and myelination in a mouse model of Pelizaeus-Merzbacher disease.
Karim SA; Barrie JA; McCulloch MC; Montague P; Edgar JM; Kirkham D; Anderson TJ; Nave KA; Griffiths IR; McLaughlin M
Glia; 2007 Mar; 55(4):341-51. PubMed ID: 17133418
[TBL] [Abstract][Full Text] [Related]
12. PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2.
Inoue K
Neurogenetics; 2005 Feb; 6(1):1-16. PubMed ID: 15627202
[TBL] [Abstract][Full Text] [Related]
13. A novel PLP1 frameshift mutation causing a milder form of Pelizaeus-Merzbacher disease.
Shiihara T; Watanabe M; Moriyama K; Uematsu M; Sameshima K
Brain Dev; 2015 Apr; 37(4):455-8. PubMed ID: 25043250
[TBL] [Abstract][Full Text] [Related]
14. The molecular and cellular defects underlying Pelizaeus-Merzbacher disease.
Woodward KJ
Expert Rev Mol Med; 2008 May; 10():e14. PubMed ID: 18485258
[TBL] [Abstract][Full Text] [Related]
15. Insertion of proteolipid protein into mitochondria but not DM20 regulates metabolism of cells.
Somayajulu M; Bessert DA; Hüttemann M; Sohi J; Kamholz J; Skoff RP
Neurosci Lett; 2018 Jun; 678():90-98. PubMed ID: 29729355
[TBL] [Abstract][Full Text] [Related]
16. Mutation of Proteolipid Protein 1 Gene: From Severe Hypomyelinating Leukodystrophy to Inherited Spastic Paraplegia.
Khalaf G; Mattern C; Begou M; Boespflug-Tanguy O; Massaad C; Massaad-Massade L
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885014
[TBL] [Abstract][Full Text] [Related]
17. Deep intronic deletion in intron 3 of PLP1 is associated with a severe phenotype of Pelizaeus-Merzbacher disease.
Yamamoto-Shimojima K; Akagawa H; Yanagi K; Kaname T; Okamoto N; Yamamoto T
Hum Genome Var; 2021 Apr; 8(1):14. PubMed ID: 33795668
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the PLP1 gene residue p. Gly198 as the molecular basis of Pelizeaus-Merzbacher phenotype.
Hoffman-Zacharska D; Kmieć T; Poznański J; Jurek M; Bal J
Brain Dev; 2013 Oct; 35(9):877-80. PubMed ID: 23245814
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
